SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, has expanded its relationship with Laboratorio Curie, a leading laboratory located in the capital city of Paraguay. Laboratorio Curie is now live on the SOPHiA DDM™ Platform and will use the technology to deploy a new test that will identify BRCA gene mutations. Discoveries made using this test aim to enable Laboratorio Curie to support the increased use of precision medicine for hereditary cancers within the country.
Laboratorio Curie has been a staple in Paraguay for more than 25 years and has been recognized nationally for its high level of scientific research. Since 2022 the Lab has worked with SOPHiA GENETICS to examine variants associated with hereditary cancers and the expansion of its relationship with SOPHiA GENETICS will allow the Lab to advance its existing research. With the SOPHiA DDM™ Platform, Laboratorio Curie will use next-generation sequencing (NGS) to screen for mutations in the BRCA genes which have been shown to be linked to an increased risk of several cancers, most notably, breast and ovarian cancer.
“At Laboratorio Curie our mission is research, even behind the most clinical analyses. It is this passion that guides us to advance science and work every day to discover ways to make a difference in people’s lives,” said Dra. Filartiga, Lab Director, Laboratorio Curie. “Thanks to the commitment, dedication, and effort of our team, today we are considered an outstanding benchmark in Paraguay. Being pioneers in precision medicine in cancer through genomics and hand in hand with SOPHiA GENETICS is a goal achieved with effort and perseverance, and we are proud to have the trust and respect of the medical community.”
The identification of BRCA mutations via NGS testing produces a vast amount of data that can be time-consuming and complex to analyze. The SOPHiA DDM™ Platform is a technology agnostic application that uses artificial intelligence (AI) to efficiently analyze and interpret raw NGS data. The SOPHiA DDM™ Platform will provide Laboratorio Curie with accurate and analyzed results in less than two days, accelerating reporting and data-driven decision-making for researchers.
“By using the SOPHiA DDM™ Platform, Laboratorio Curie can ensure speed and accuracy of its NGS testing to best support investigations into BRCA-associated cancers. Additionally, the Lab will be able to amass a database of BRCA research that will map a more holistic view of how BRCA is impacting South Americans.” said Ricardo Mendonca Filho, Ph.D., Managing Director, LAPAC, SOPHiA GENETICS.
SOURCE: PRNewswire
